Stock Analiz

Iradimed Corp. (IRMD) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Iradimed’s revenue went from $32M in fiscal 2016 to $84M in fiscal 2025, growth of about 11.1% a year.

Net income in fiscal 2025 was $22M, a net margin of 26.8%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $89M and net income $24M.

Free cash flow was $17M in fiscal 2025 and positive in 10 of the 10 years shown.

The diluted share count rose 7% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $32M162017: $23M172018: $30M182019: $39M192020: $32M202021: $42M212022: $53M222023: $66M232024: $73M242025: $84M25$84M
Net income
2016: $7M162017: $499764172018: $6M182019: $10M192020: $1M202021: $9M212022: $13M222023: $17M232024: $19M242025: $22M25$22M
Free cash flow
2016: $9M162017: $3M172018: $7M182019: $10M192020: $5M202021: $11M212022: $9M222023: $6M232024: $18M242025: $17M25$17M
EPS (diluted)
2016: $0.60162017: $0.04172018: $0.52182019: $0.78192020: $0.11202021: $0.74212022: $1.02222023: $1.35232024: $1.50242025: $1.7525$1.75

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$89M$84M$73M$66M$53M$42M$32M$39M$30M$23M$32M
Gross profit$67M$64M$56M$50M$41M$32M$24M$30M$23M$18M$26M
Operating income$29M$26M$22M$20M$16M$10M-$756091$9M$6M$1M$11M
Net income$24M$22M$19M$17M$13M$9M$1M$10M$6M$499764$7M
EPS (diluted)$1.87$1.75$1.50$1.35$1.02$0.74$0.11$0.78$0.52$0.04$0.60
R&D$3M$3M$3M$3M$2M$2M$2M$1M$2M$2M$1M
Revenue growth—+14.4%+11.7%+23.0%+27.5%+31.8%−17.6%+26.5%+31.9%−29.0%+2.9%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$27M$25M$26M$13M$10M$11M$6M$10M$7M$3M$9M
Capital spending-$1M-$8M-$8M-$7M-$823019-$482325-$443003-$368281-$228315-$775574-$780809
Free cash flow$26M$17M$18M$6M$9M$11M$5M$10M$7M$3M$9M
Dividends paid$16M$15M$14M$13M$13M——————
Buybacks—————————$2M$10M
Stock-based pay$3M$3M$3M$2M$1M$1M$4M$2M$2M$2M$2M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$51M$52M$50M$58M$63M$52M$46M$34M$26M$18M
Debt—$0$154688$2M$3M$2M$3M$3M$0$0$0
Equity—$95M$87M$71M$74M$72M$61M$56M$42M$33M$32M
Total assets—$109M$98M$92M$86M$83M$71M$67M$48M$39M$37M
Shares (diluted)13M13M13M13M13M13M12M12M12M12M12M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin75.5%76.8%76.9%76.5%77.5%76.6%74.3%77.1%76.3%75.9%81.1%
Operating margin32.3%31.2%30.0%30.6%29.3%23.5%-2.4%22.4%19.7%5.6%33.6%
Net margin26.8%26.8%26.3%26.2%24.1%22.3%4.3%25.0%20.7%2.2%22.2%
FCF margin29.3%20.5%24.1%9.2%17.3%25.8%16.9%25.6%23.5%11.4%26.5%
ROIC—21.9%20.0%21.6%16.2%12.5%-0.9%11.7%11.3%3.1%22.6%
ROE—23.8%22.1%24.1%17.4%12.9%2.2%17.3%15.0%1.5%22.6%

Frequently asked questions

What is Iradimed’s annual revenue?

$84M in fiscal 2025 and $89M over the twelve months to September 30, 2026.

How much profit does Iradimed make?

Net income was $22M in fiscal 2025 (net margin 26.8%).

Is Iradimed’s revenue growing?

Yes: revenue rose 14.4% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.